Acadia Pharmaceuticals Inc ACAD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
-
Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041
-
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)
-
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
-
Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results
-
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference
-
Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis
-
Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026
Trading Information
- Previous Close Price
- $20.15
- Day Range
- $19.59–20.19
- 52-Week Range
- $19.59–30.96
- Bid/Ask
- $19.45 / $20.72
- Shares Outstanding
- 172.31M
- Market Cap
- $3.43B
- Volume/Avg
- 3M / 2M
Key Statistics
- Price/Earnings (Normalized)
- 32.19
- Price/Sales
- 3.01
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise into making a difference for underserved neurological and rare disease communities around the world. It has two franchises in neurological and rare diseases. Its neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 798
- Website
- https://www.acadia.com
Valuation
|
Metric
|
ACAD
|
|---|---|
Price/Earnings (Normalized) | 32.19 |
Price/Book Value | 2.62 |
Price/Sales | 3.01 |
Price/Cash Flow | 16.47 |
Price/Earnings
ACAD
Financial Strength
|
Metric
|
ACAD
|
|---|---|
Quick Ratio | 3.11 |
Current Ratio | 3.39 |
Interest Coverage | — |
Quick Ratio
ACAD
Profitability
|
Metric
|
ACAD
|
|---|---|
Return on Assets (Normalized) | 28.54% |
Return on Equity (Normalized) | 38.61% |
Return on Invested Capital (Normalized) | 34.47% |
Return on Assets
ACAD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|?fTH%$ | LOCK|$>&&N | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|wDwKJ? | LOCK|!T@X | $76B | |||
| Moderna Inc
MRNA
| LOCK|q#>rmW | LOCK|P# | $75B | |||
| argenx SE ADR
ARGX
| LOCK|rt$TGr& | LOCK|njt | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|$tf><D | LOCK|@X | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|%@?HrFK | LOCK|!^#% | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|H>n%Rm^@ | LOCK|Zww< | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|v^?cwX | LOCK|$C | $24B | |||
| Incyte Corp
INCY
| LOCK|Y<l?!% | LOCK|T^> | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|FWch%#< | LOCK|@Z | $15B |
United States